Eisai Announces New Research at the 2017 Alzheimer's Association International Conference® (AAIC®)

WOODCLIFF LAKE, N.J., July 17, 2017 /PRNewswire/ -- Eisai Inc. announced today the presentation of eight posters, including safety data on three different compounds in its Alzheimer's disease portfolio, at the Alzheimer's Association International Conference® (AAIC®) 2017 in London from July 16-20, 2017. In addition, Eisai will host a symposium discussing BACE inhibition as a therapeutic target for Alzheimer's disease on Monday, July 17(th). AAIC is the premier annual conference for presentation and discussion of the latest Alzheimer's and dementia research.

"The data being presented at the AAIC demonstrate our commitment to people living with Alzheimer's disease and dementia as well as the healthcare providers who care for these patients," said Lynn Kramer, M.D., Chief Clinical Officer and Chief Medical Officer, Neurology Business Group, Eisai. ( )

The following data will be presented by Eisai at this year's AAIC:

    Abstract Name                                            Date/Session
    -------------                                            ------------


    Elenbecestat, a novel oral BACE
     inhibitor, has no clinically meaningful
     effect on QTc interval up to a
     supratherapeutic dose of 200mg          Date: July 16

                                             9:30-4:15 pm


                                             Abstract 19055
    ---                                      --------------

    Elenbecestat pharmacokinetic drug-drug
     interactions indicated no dosage
     adjustments required for most
     concomitant treatments                  Date: July 17

                                             9:30-4:45 pm


                                             Abstract ID 19157
    ---                                      -----------------

    Preclinical studies with elenbecestat, a
     novel BACE inhibitor, show no evidence
     of hypopigmentation                     Date: July 18


                                             Abstract ID: 18045
    ---                                      ------------------


    Pharmacologic characterization of
     BAN2401-mediated A  protofibril
     clearance by microglia                  Date: July 17

                                             9:30-4:45 pm


                                             Abstract ID 19125
    ---                                      -----------------


    Population pharmacokinetic-
     pharmacodynamic (PPK/PD) modeling of
     E2027, a selective phosphodiesterase-9
     inhibitor, following single ascending
     oral doses in healthy volunteers        Date: July 16

                                             9:30-4:15 pm


                                             Abstract ID: 17550
    ---                                      ------------------

    Phase 1 investigation into the safety,
     tolerability, pharmacokinetics and
     pharmacodynamics of E2027, a selective
     phosphodiesterase-9 (PDE9) inhibitor    Date: July 17

                                             9:30-4:45 pm


                                             Abstract ID 17712
    ---                                      -----------------

    Preclinical characterization of E2027, a
     novel phosphodiesterase 9 inhibitor     Date: July 18

                                             9:30-4:15 pm


                                             Abstract ID: 17832
    ---                                      ------------------


    The financial capacity instrument (FCI):
     short form is a novel, performance-
     based measure that may help
     differentiate mild cognitive impairment
     and mild dementia due to Alzheimer's
     Disease populations in clinical trials  Date: July 16

                                             9:30-4:45 pm


                                             Abstract ID 18497
    ---                                      -----------------

Elenbecestat and BAN2401 are being jointly developed by Eisai and Biogen.

This release discusses investigational agents in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that these investigational agents will successfully complete clinical development or gain FDA approval.

About Eisai Inc.
At Eisai Inc., human health care (hhc) is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.

Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US.


    Media Inquiries                Investor Inquiries

    Laurie Landau                  Ivor Macleod

    Eisai Inc.                     Eisai Inc.

    201-746-2510                   201-746-2660

View original content with multimedia:http://www.prnewswire.com/news-releases/eisai-announces-new-research-at-the-2017-alzheimers-association-international-conference-aaic-300488864.html

SOURCE Eisai Inc.